Last edition
News about "Office of Manufacturing Quality"
US FDA Classifies Biocon Biologics' Bengaluru Drug Substance Facility as VAI
The US FDA has classified Biocon Biologics’ Bengaluru drug substance facility as Voluntary Action Indicated (VAI) following an inspection in August–September 2025. The review covers the site’s production of rh-Insulin and biosimilar Pegfilgrastim for the US market.
Office Of Manufacturing Quality | 29/11/2025 | By Dineshwori | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members